THE RELATIONSHIP BETWEEN C-MYC PROTEIN EXPRESSION, THE BROMODEOXYURIDINE LABELING INDEX AND THE BIOLOGICAL BEHAVIOR OF PITUITARY-ADENOMAS

被引:35
作者
IKEDA, H
YOSHIMOTO, T
机构
[1] Division of Neurosurgery, Institute of Brain Diseases, Tohoku University School of Medicine, Sendai, 980, Seiryo-machi, Aoba-ku
关键词
C-MYC PROTEIN; BROMODEOXYURIDINE; PITUITARY ADENOMA; MALIGNANCY; LABELING INDEX;
D O I
10.1007/BF00713526
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To clarify the relationship between the percentage of c-myc protein-labeled cells, the bromodeoxyuridine (BrdUrd) labeling index (LI) and clinical malignancy in pituitary adenomas,we studied 31 cases of pituitary adenomas. Tumor invasiveness, recurrence, tumor size and the length of illness were evaluated from operative findings, magnetic resonance imaging findings, and the clinical course. Each pituitary adenoma was scored to represent the degree of clinical malignancy. An hour before excision of the tumor, we administered BrdUrd intravenously. Surgical materials were fixed in 70% alcohol and embedded in paraffin. Both hematoxylin and eosin staining and immunohistochemical staining were performed using a monoclonal antibody for both anti-BrdUrd and anti-c-myc protein. Among pituitary adenomas, there was a significantly low percentage of c-myc protein-labeled cells in cases with acromegaly. The percentage of c-myc protein-labeled cells in the pituitary adenomas tended to increase with increase with the total scores of clinical malignancy. The BrdUrd LI was lower than 1% in almost all cases of pituitary adenomas, and it showed no correlation with their clinical malignancy. In conclusion, determination of the percentage of c-myc protein-labeled cells in pituitary adenomas proved to be useful for evaluating their clinical malignancy.
引用
收藏
页码:361 / 364
页数:4
相关论文
共 24 条
[1]  
ANNIKO M, 1984, CANCER, V53, P1708, DOI 10.1002/1097-0142(19840415)53:8<1708::AID-CNCR2820530815>3.0.CO
[2]  
2-L
[3]   NUCLEAR-LOCALIZATION AND DNA-BINDING OF THE TRANSFORMING GENE-PRODUCT OF AVIAN MYELOCYTOMATOSIS VIRUS [J].
DONNER, P ;
GREISERWILKE, I ;
MOELLING, K .
NATURE, 1982, 296 (5854) :262-266
[4]   EXPRESSION OF C-FOS AND C-MYC PROTO-ONCOGENES IN HUMAN ADRENAL PHEOCHROMOCYTOMAS [J].
GOTO, K ;
OGO, A ;
YANASE, T ;
HAJI, M ;
OHASHI, M ;
NAWATA, H .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (02) :353-357
[6]   USE OF AVIDIN-BIOTIN-PEROXIDASE COMPLEX (ABC) IN IMMUNOPEROXIDASE TECHNIQUES - A COMPARISON BETWEEN ABC AND UNLABELED ANTIBODY (PAP) PROCEDURES [J].
HSU, SM ;
RAINE, L ;
FANGER, H .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1981, 29 (04) :577-580
[7]   POSSIBLE FUNCTION OF THE C-MYC PRODUCT - PROMOTION OF CELLULAR DNA-REPLICATION [J].
IGUCHIARIGA, SMM ;
ITANI, T ;
KIJI, Y ;
ARIGA, H .
EMBO JOURNAL, 1987, 6 (08) :2365-2371
[8]   C-MYC PROTEIN CAN BE SUBSTITUTED FOR SV40-T ANTIGEN IN SV40-DNA REPLICATION [J].
IGUCHIARIGA, SMM ;
ITANI, T ;
YAMAGUCHI, M ;
ARIGA, H .
NUCLEIC ACIDS RESEARCH, 1987, 15 (12) :4889-4899
[9]   DEVELOPMENTAL-CHANGES IN PROLIFERATIVE ACTIVITY OF CELLS OF THE MURINE RATHKES POUCH [J].
IKEDA, H ;
YOSHIMOTO, T .
CELL AND TISSUE RESEARCH, 1991, 263 (01) :41-47
[10]   CELL-SPECIFIC REGULATION OF THE C-MYC-GENE BY LYMPHOCYTE MITOGENS AND PLATELET-DERIVED GROWTH-FACTOR [J].
KELLY, K ;
COCHRAN, BH ;
STILES, CD ;
LEDER, P .
CELL, 1983, 35 (03) :603-610